EE03204B1 - Toimeaine flupirtiini kasutamine ravimi valmistamiseks - Google Patents

Toimeaine flupirtiini kasutamine ravimi valmistamiseks

Info

Publication number
EE03204B1
EE03204B1 EE9400160A EE9400160A EE03204B1 EE 03204 B1 EE03204 B1 EE 03204B1 EE 9400160 A EE9400160 A EE 9400160A EE 9400160 A EE9400160 A EE 9400160A EE 03204 B1 EE03204 B1 EE 03204B1
Authority
EE
Estonia
Prior art keywords
pct
medicament
manufacture
active ingredient
flupirtine
Prior art date
Application number
EE9400160A
Other languages
English (en)
Inventor
Schwarz Michael
Pergande Gabriela
Engel J�rgen
Nickel Bernd
Ulrich Heinz
Szelenyi Stefan
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Publication of EE03204B1 publication Critical patent/EE03204B1/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Confectionery (AREA)
  • Medicinal Preparation (AREA)
EE9400160A 1993-08-17 1994-10-25 Toimeaine flupirtiini kasutamine ravimi valmistamiseks EE03204B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4327516A DE4327516A1 (de) 1993-08-17 1993-08-17 Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Publications (1)

Publication Number Publication Date
EE03204B1 true EE03204B1 (et) 1999-08-16

Family

ID=6495312

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400160A EE03204B1 (et) 1993-08-17 1994-10-25 Toimeaine flupirtiini kasutamine ravimi valmistamiseks

Country Status (27)

Country Link
US (1) US5721258A (et)
EP (1) EP0716602B1 (et)
JP (1) JPH09501664A (et)
KR (1) KR100341952B1 (et)
CN (1) CN1086291C (et)
AT (1) ATE210442T1 (et)
AU (1) AU694447B2 (et)
BG (1) BG62430B1 (et)
BR (1) BR9407293A (et)
CA (1) CA2169718C (et)
CZ (1) CZ289040B6 (et)
DE (2) DE4327516A1 (et)
DK (1) DK0716602T3 (et)
EE (1) EE03204B1 (et)
ES (1) ES2168309T3 (et)
HR (1) HRP940464A2 (et)
HU (1) HU227765B1 (et)
IL (1) IL110681A (et)
NO (1) NO309842B1 (et)
NZ (1) NZ273292A (et)
PT (1) PT716602E (et)
RU (1) RU2166318C2 (et)
SK (1) SK283330B6 (et)
UA (1) UA43351C2 (et)
WO (1) WO1995005175A1 (et)
YU (1) YU49215B (et)
ZA (1) ZA946176B (et)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
AU9646298A (en) * 1997-10-27 1999-05-17 Sumitomo Pharmaceuticals Company, Limited Amide derivatives
WO2001034172A2 (en) * 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
AU1353901A (en) * 1999-12-01 2001-06-12 Duke University Method of treating batten disease
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
US8334263B2 (en) * 2003-12-16 2012-12-18 Raymond Nadeson Analgesic methods and compositions
EP1831170A4 (en) * 2004-12-14 2009-10-14 Astrazeneca Ab SUBSTITUTED AMINOPYRIDINES AND THEIR USE
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20060258708A1 (en) * 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP2016527270A (ja) * 2013-07-31 2016-09-08 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびフルピルチンの組合せによる多発性硬化症の治療
US11369593B2 (en) * 2017-07-14 2022-06-28 Texas Tech University System Functionalized pyridine carbamates with enhanced neuroprotective activity
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481205A (en) * 1980-09-13 1984-11-06 Degussa Aktiengesellschaft 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate
EP0110091B1 (de) * 1982-10-27 1987-01-21 Degussa Aktiengesellschaft 2-Amino-3-Acylamino-6-benzylamino-pyridin-Derivate mit anti-epileptischer Wirkung
DE3337593A1 (de) * 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
NO860825L (no) * 1985-03-23 1986-09-24 Degussa Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin.
IN172468B (et) * 1990-07-14 1993-08-14 Asta Medica Ag

Also Published As

Publication number Publication date
UA43351C2 (uk) 2001-12-17
WO1995005175A1 (en) 1995-02-23
DE4327516A1 (de) 1995-02-23
NO309842B1 (no) 2001-04-09
NO960607L (no) 1996-02-15
ATE210442T1 (de) 2001-12-15
KR960703591A (ko) 1996-08-31
YU51294A (sh) 1998-05-15
HU9600355D0 (en) 1996-04-29
SK283330B6 (sk) 2003-06-03
BR9407293A (pt) 1996-10-01
JPH09501664A (ja) 1997-02-18
CA2169718A1 (en) 1995-02-23
US5721258A (en) 1998-02-24
KR100341952B1 (ko) 2003-04-11
CN1086291C (zh) 2002-06-19
DK0716602T3 (da) 2002-03-25
EP0716602B1 (en) 2001-12-12
YU49215B (sh) 2004-11-25
PT716602E (pt) 2002-05-31
ES2168309T3 (es) 2002-06-16
RU2166318C2 (ru) 2001-05-10
HRP940464A2 (en) 1997-06-30
CZ46596A3 (en) 1996-05-15
BG62430B1 (bg) 1999-11-30
CA2169718C (en) 2002-11-12
AU7652894A (en) 1995-03-14
HUT75650A (en) 1997-05-28
AU694447B2 (en) 1998-07-23
ZA946176B (en) 1995-03-20
CZ289040B6 (cs) 2001-10-17
CN1129399A (zh) 1996-08-21
IL110681A (en) 1999-08-17
NO960607D0 (no) 1996-02-15
BG100356A (bg) 1996-07-31
IL110681A0 (en) 1994-11-11
EP0716602A1 (en) 1996-06-19
DE69429435D1 (de) 2002-01-24
DE69429435T2 (de) 2002-06-13
SK21496A3 (en) 1997-01-08
NZ273292A (en) 1999-09-29
HU227765B1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
EE03204B1 (et) Toimeaine flupirtiini kasutamine ravimi valmistamiseks
PT703786E (pt) Utilizacao de nonapeptideos e decapeptideos para a preparacao de um medicamento para o tratamento da sida
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
AU678795B2 (en) Application of riluzole in the treatment of neurological lesions related to traumatic injuries
CA2436799A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
HK1004257A1 (en) Use of droloxifene in the treatment of bone diseases
ZA938421B (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders
ZA94413B (en) Pharmaceutical formulation for the treatment of nicotine dependence
EP0744176A3 (en) Methods for inhibiting bone loss
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
BR9406865A (pt) Uso de um sal farmaceuticamente aceitável de ropivacaina na fabricaçao de um produto farmaceutico processo para o tratamento de uma pessoa necessitando de alivio da dor e preparaçao farmaceutica
HUT70521A (en) Process to prepare pharmaceutical comps. again amyloidosis

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231